"A study, published on Wednesday in the New England Journal of Medicine, showed that last season's 20242025 mRNA COVID vaccines reduced people's risk of emergency department visits by 29 percent, their risk of hospitalizations by 39 percent and their risk of death by 64 percent. Of the nearly 300,000 U.S. participants in the study, 35 percent received the Pfizer vaccine (COMIRNATY), and 64 percent received the Moderna vaccine (Spikevax)."
"The research is in line with what scientists have seen in previous years. The vaccine is efficacious, particularly against severe disease, says Stanley Perlman, a coronavirus researcher and a professor of microbiology and immunology at the University of Iowa, who was not involved in the study. And he and other experts expect the new 20252026 COVID vaccines' performance will follow suit."
Last season's 2024–2025 mRNA COVID vaccines reduced emergency department visit risk by 29 percent, hospitalization risk by 39 percent, and death risk by 64 percent among nearly 300,000 U.S. participants. Thirty-five percent of participants received Pfizer (COMIRNATY) and 64 percent received Moderna (Spikevax). Vaccination was effective across all age groups and among persons with or without major chronic conditions. Vaccine effectiveness against symptomatic disease has waned since 2019; the 2024–2025 shots offered 29–64 percent protection compared with 94 percent protection in 2019. This waning is expected in a population with some prior immunity, and new 2025–2026 vaccines are anticipated to perform similarly.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]